Edoxaban and Gastrointestinal haemorrhage - a phase IV clinical study of FDA data

Summary:

Gastrointestinal haemorrhage is reported as a side effect among people who take Edoxaban (edoxaban), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Simvastatin, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Gastrointestinal haemorrhage when taking Edoxaban. It is created by eHealthMe based on reports of 1,775 people who have side effects when taking Edoxaban from the FDA, and is updated regularly.

What is Edoxaban?

Edoxaban has active ingredients of edoxaban. eHealthMe is studying from 1,783 Edoxaban users. Check the latest studies of Edoxaban.

What is Gastrointestinal haemorrhage?

Gastrointestinal haemorrhage (bleeding gastrointestinal tract) is found to be associated with 2,096 drugs and 2,031 conditions by eHealthMe. Check the latest studies of Gastrointestinal haemorrhage.

On Jul, 08, 2026

1,775 people reported to have side effects when taking Edoxaban.
Among them, 64 people (3.61%) have Gastrointestinal haemorrhage.

Could Edoxaban cause Gastrointestinal haemorrhage?

Among these 64 people:

How long have people been on Edoxaban when they have Gastrointestinal haemorrhage? *

What is the gender of people who have Gastrointestinal haemorrhage when taking Edoxaban? *

female: 50 %
male: 50 %

What is the age of people who have Gastrointestinal haemorrhage when taking Edoxaban? *

What are other drugs people take besides Edoxaban? *

What are other side effects people have besides Gastrointestinal haemorrhage? *

Anaemia (lack of blood): 18 people, 28.12%
Shock Haemorrhagic (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin due to excess bleeding): 15 people, 23.44%
Hypotension (abnormally low blood pressure): 12 people, 18.75%
Renal Impairment (severely reduced kidney function): 10 people, 15.62%
Dyspnea (difficult or laboured breathing): 9 people, 14.06%
Haematochezia (passage of stools containing blood): 9 people, 14.06%
Paleness (unusual lightness of skin colour): 9 people, 14.06%
Fall: 8 people, 12.50%
Melaena (the passage of black, tarry stools): 8 people, 12.50%
General Physical Health Deterioration (weak health status): 7 people, 10.94%

What are the existing conditions these people have? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 18 people, 28.12%
Cardiac Failure: 7 people, 10.94%
High Blood Pressure: 5 people, 7.81%
Acute Myocardial Infarction (acute heart attack): 4 people, 6.25%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 4 people, 6.25%
Breast Cancer: 4 people, 6.25%
Diabetes: 3 people, 4.69%
Type 2 Diabetes: 3 people, 4.69%
Oedema Due To Cardiac Disease (fluid collection in tissue due to heart disease): 2 people, 3.12%
Heart Attack: 2 people, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Edoxaban and have Gastrointestinal haemorrhage?

- Check whether Gastrointestinal haemorrhage is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Edoxaban:

Edoxaban (1,783 reports)

Browse all side effects of Edoxaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal haemorrhage:

Gastrointestinal haemorrhage (2,097 drugs)

Browse all the conditions that are associated with Gastrointestinal haemorrhage:

Gastrointestinal haemorrhage (2,031 conditions)

Related publications that referenced our studies

Alokaily FA, Alghamdi M, Almalki AS, Alhussaini H, "Aspirin induced leukocytoclastic vasculitis, lower gastrointestinal hemorrhage and acute renal failure (mimicking systemic vasculitis)", Saudi medical journal, 2013 Apr .
Alokaily FA, Alghamdi M, Almalki AS, Alhussaini H, "Aspirin induced leukocytoclastic vasculitis, lower gastrointestinal hemorrhage and acute renal failure (mimicking systemic vasculitis)", Saudi medical journal, 2013 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on edoxaban (the active ingredients of Edoxaban) and Edoxaban (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.